Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.66 |
| ▸ | BRD4 | O60885 | 12/20 | 0.66 |
| ▸ | BRDT | Q58F21 | 6/20 | 0.66 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.61 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.61 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.61 |
| ▸ | RAD52 | P43351 | 1/20 | 0.59 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4111700 | 0.96 | PLK1 (0.72) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL3547749 | 0.94 | PLK1 (0.61) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL3543178 | 0.90 | PLK1 (0.64) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL1560566 | 0.89 | PLK1 (0.80) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL4302524 | 0.89 | PLK1 (0.81) | PLK1BRD4BRDTRAD52PLK3 | |
| SCHEMBL2396452 | 0.89 | PLK1 (0.81) | PLK1BRD4BRDTRAD52PLK3 | |
| SCHEMBL2396449 | 0.89 | PLK1 (0.81) | PLK1BRD4BRDTRAD52PLK3 | |
| SCHEMBL3543832 | 0.88 | PLK1 (0.68) | PLK1BRD4BRDTPLK3 | |
| SCHEMBL12880122 | 0.88 | PLK1 (0.71) | PLK1BRD4BRDTDCLK1LRRK2 | |
| SCHEMBL2397069 | 0.87 | PTK2 (0.58) | PLK1BRD4BRDTDCLK1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | PLK1 847/4885BRD4 2662/4885BRDT 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.